International Journal of Hematology

, Volume 87, Issue 1, pp 56–59

Dramatic remission of anemia after thymectomy in a patient of idiopathic myelofibrosis with thymoma

  • Ying-Yih Shih
  • Liang-Tsai Hsiao
  • Ching-Fen Yang
  • Yu-Chung Wu
  • Tzeon-Jye Chiou
Case Report
  • 69 Downloads

Abstract

Anemia is one of the characteristics of idiopathic myelofibrosis (IMF), and malignant thymoma is usually associated with various hematologic disorders, including anemia, pancytopenia, and hypogammaglobulinemia. However, the relationship between IMF and malignant thymoma has not been published before. Here, we report a 48-year-old woman who was initially diagnosed of IMF with severe anemia and transfusion dependent. Five years later, malignant thymoma was found when she was examined for chronic cough. After performing extended thymectomy, her anemia dramatically recovered to normal and sustained for 2 years till last follow-up. Her splenomegaly and myelofibrosis were also improved. We hypothesized that her malignant thymoma induced the progression of IMF, especially in anemia.

Keywords

Anemia Danazol Idiopathic myelofibrosis Thymectomy Thymoma 

References

  1. 1.
    Lichtman MA. Idiopathic myelofibrosis (myelofibrosis with myeloid metaplasia). In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, editors. Williams hematology. 7th ed. New York: McGraw-Hill; 2006. p. 1295–313.Google Scholar
  2. 2.
    Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Lyon: IARC; 2001. p. 35–8.Google Scholar
  3. 3.
    Reilly JT. Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol. 2006;24:56–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenow EC 3rd, Hurley BT. Disorders of the thymus. A review. Arch Intern Med. 1984;144:763–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Rubinstein I, Langevitz P, Hirsch R, Berkowicz M, Lieberman Y, Shibi G. Autoimmune hemolytic anemia as the presenting manifestation of malignant thymoma. Acta Haematol. 1985;74:40–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. Coincidence or syndrome? Arch Intern Med. 1974;134:374–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005;106:2849–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–65.PubMedCrossRefGoogle Scholar
  9. 9.
    Lippman SM, Durie BG, Garewal HS, Giordano G, Greenberg BR. Efficacy of danazol in pure red cell aplasia. Am J Hematol. 1986;23:373–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Tan AM, Lou J, Cheng HK. Danazol for treatment of refractory autoimmune hemolytic anaemia. Ann Acad Med Singapore. 1989;18:707–9.PubMedGoogle Scholar
  11. 11.
    Shichino H, Mugishima H, Takamura M, Shimada T, Suzuki T, Chin M, et al. Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazol and recombinant human granulocyte-colony stimulating factor. Acta Paediatr Jpn. 1996;38:644–7.PubMedGoogle Scholar
  12. 12.
    Murakawa M, Shibuya T, Harada M, Okamura T, Asano Y, Okamura H, et al. Danazol treatment for paroxysmal nocturnal hemoglobinuria. Jpn J Med. 1990;29:417–22.PubMedGoogle Scholar
  13. 13.
    Sadek I, Zayed E, Hayne O, Fernandez L. Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone. Am J Hematol. 2000;64:306–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85:595–9.PubMedGoogle Scholar
  15. 15.
    Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129:771–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Velazquez I, Alter BP. Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions. Am J Hematol. 2004;77:257–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Cottreau CM, Ness RB, Modugno F, Allen GO, Goodman MT. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res. 2003;9:5142–4.PubMedGoogle Scholar
  18. 18.
    Krantz SB. Diagnosis and treatment of pure red cell aplasia. Med Clin North Am. 1976;60:945–58.PubMedGoogle Scholar
  19. 19.
    Rennenberg RJ, Pauwels P, Vlasveld LT. A case of thymoma-associated autoimmune haemolytic anaemia. Neth J Med. 1997;50:110–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72:8–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis––pathophysiological implications. Am J Hematol. 1998;59:133–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Abe Y, Ohshima K, Shiratsuchi M, Honda K, Nishimura J, Nawata H, et al. Cytotoxic T-cell lymphoma presenting as secondary myelofibrosis with high levels of PDGF and TGF-beta. Eur J Haematol. 2001;66:210–2.PubMedCrossRefGoogle Scholar
  23. 23.
    Altomare G, Capella GL, Frigerio E. Sweet’s syndrome in a patient with idiopathic myelofibrosis and thymoma–myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate. Haematologica. 1996;81:54–8.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Ying-Yih Shih
    • 1
    • 4
  • Liang-Tsai Hsiao
    • 1
  • Ching-Fen Yang
    • 2
  • Yu-Chung Wu
    • 3
  • Tzeon-Jye Chiou
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineTaipei Veterans General Hospital, National Yang-Ming University School of MedicineTaipeiTaiwan
  2. 2.Department of PathologyTaipei Veterans General HospitalTaipeiTaiwan
  3. 3.Division of Thoracic Surgery, Department of SurgeryTaipei Veterans General HospitalTaipeiTaiwan
  4. 4.Division of Hematology and Oncology, Department of MedicineCathay General HospitalTaipeiTaiwan

Personalised recommendations